Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Silence Therapeutics plc reported the fourth quarter and full year ended December 31, 2025 results: revenue $0.6 million, net income $88.6 million, EPS $0.63 basic and diluted net loss per share.
- Period
- the fourth quarter and full year ended December 31, 2025
- Revenue
- $0.6 million
- Net income
- $88.6 million
- EPS
- $0.63 basic and diluted net loss per share
- Result
- reported results
Exact text from the filing
Full Year 2025 Financial Results • Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million. • Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration. • R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024. • G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primaril
View on SEC.gov